Servier shared a post on LinkedIn:
“In 2024/2025, the Group demonstrates its global presence and unwavering commitment to patients.
With more than 20,000 dedicated employees working across over 130 countries, the Group combines scientific expertise, industrial capabilities, and a strong international network to bring its treatments to patients worldwide. From research laboratories to manufacturing sites and local affiliates, our teams collaborate every day to develop, produce, and deliver 29 brand-name medicines that address major therapeutic needs.
This global presence allows us to connect innovation, production, and patient access, ensuring that therapies can reach those who need them most, wherever they are
These figures illustrate not only our scale but also the daily efforts of teams collaborating across research, industrial operations, and patient support. Every action is aimed at advancing therapeutic progress and addressing critical healthcare needs.
Explore our global footprint and achievements in the 2024/2025 report.”
Other articles from Servier.